Zurampic Approval History
Marketing Status: Discontinued
Zurampic (lesinurad) is a URAT1 inhibitor indicated for the combination treatment of hyperuricemia associated with gout.
On April 15, 2019, the FDA announced the discontinuation of Zurampic (lesinurad). The discontinuation was due to business reasons, and not due to any safety, efficacy or quality issues. The discontinuation was effective as of February 1, 2019.
Development History and FDA Approval Process for Zurampic
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.